Palisade Bio reports 47.5% reduction in endoscopic disease activity in five-patient Crohn's trial

• Palisade Bio presented early PALI-2108 trial findings at UEG Week 2026, held Oct. 17-20 in Barcelona.
• Five patients with fibrostenotic Crohn's disease showed reduced intestinal inflammation and improved endoscopic disease activity during 14 days of treatment.
• All five ulcerative colitis patients achieved clinical response by day seven; two reached clinical remission.
• The Phase 2b ASCENTRA-UC trial is enrolling approximately 204 patients; a Phase 2a Crohn's disease study is being initiated.
• The small, short-duration, uncontrolled studies require confirmation in larger controlled trials and do not establish durable benefit or reversal of intestinal fibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200805PRIMZONEFULLFEED9848887) on October 20, 2026, and is solely responsible for the information contained therein.